346 related articles for article (PubMed ID: 23580590)
1. Current mouse and cell models in prostate cancer research.
Wu X; Gong S; Roy-Burman P; Lee P; Culig Z
Endocr Relat Cancer; 2013 Aug; 20(4):R155-70. PubMed ID: 23580590
[TBL] [Abstract][Full Text] [Related]
2. Conditional expression of human 15-lipoxygenase-1 in mouse prostate induces prostatic intraepithelial neoplasia: the FLiMP mouse model.
Kelavkar UP; Parwani AV; Shappell SB; Martin WD
Neoplasia; 2006 Jun; 8(6):510-22. PubMed ID: 16820097
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
4. Advances in mouse models of prostate cancer.
Ahmad I; Sansom OJ; Leung HY
Expert Rev Mol Med; 2008 Jun; 10():e16. PubMed ID: 18538039
[TBL] [Abstract][Full Text] [Related]
5. TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation.
Casey OM; Fang L; Hynes PG; Abou-Kheir WG; Martin PL; Tillman HS; Petrovics G; Awwad HO; Ward Y; Lake R; Zhang L; Kelly K
PLoS One; 2012; 7(7):e41668. PubMed ID: 22860005
[TBL] [Abstract][Full Text] [Related]
6. Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
Kasper S
J Cell Biochem; 2005 Feb; 94(2):279-97. PubMed ID: 15565647
[TBL] [Abstract][Full Text] [Related]
7. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
9. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in prostate cancer research: large-scale genomic analyses reveal novel driver mutations and DNA repair defects.
Frank S; Nelson P; Vasioukhin V
F1000Res; 2018; 7():. PubMed ID: 30135717
[TBL] [Abstract][Full Text] [Related]
11. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional regulation of the
Xie Q; Wang ZA
J Biol Chem; 2017 Aug; 292(33):13521-13530. PubMed ID: 28679531
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
14. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
15. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
16. New therapy targeting differential androgen receptor signaling in prostate cancer stem/progenitor vs. non-stem/progenitor cells.
Lee SO; Ma Z; Yeh CR; Luo J; Lin TH; Lai KP; Yamashita S; Liang L; Tian J; Li L; Jiang Q; Huang CK; Niu Y; Yeh S; Chang C
J Mol Cell Biol; 2013 Feb; 5(1):14-26. PubMed ID: 22831834
[TBL] [Abstract][Full Text] [Related]
17. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer.
Cai C; Wang H; He HH; Chen S; He L; Ma F; Mucci L; Wang Q; Fiore C; Sowalsky AG; Loda M; Liu XS; Brown M; Balk SP; Yuan X
J Clin Invest; 2013 Mar; 123(3):1109-22. PubMed ID: 23426182
[TBL] [Abstract][Full Text] [Related]
18. Amino-terminal enhancer of split gene AES encodes a tumor and metastasis suppressor of prostate cancer.
Okada Y; Sonoshita M; Kakizaki F; Aoyama N; Itatani Y; Uegaki M; Sakamoto H; Kobayashi T; Inoue T; Kamba T; Suzuki A; Ogawa O; Taketo MM
Cancer Sci; 2017 Apr; 108(4):744-752. PubMed ID: 28178391
[TBL] [Abstract][Full Text] [Related]
19. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA LINC00963 induces NOP2 expression by sponging tumor suppressor miR-542-3p to promote metastasis in prostate cancer.
Sun F; Wu K; Yao Z; Mu X; Zheng Z; Sun M; Wang Y; Liu Z; Zhu Y
Aging (Albany NY); 2020 Jun; 12(12):11500-11516. PubMed ID: 32554858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
